JP2007516194A5 - - Google Patents

Download PDF

Info

Publication number
JP2007516194A5
JP2007516194A5 JP2006518329A JP2006518329A JP2007516194A5 JP 2007516194 A5 JP2007516194 A5 JP 2007516194A5 JP 2006518329 A JP2006518329 A JP 2006518329A JP 2006518329 A JP2006518329 A JP 2006518329A JP 2007516194 A5 JP2007516194 A5 JP 2007516194A5
Authority
JP
Japan
Prior art keywords
group
hydrogen
substituents
optionally substituted
groups
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2006518329A
Other languages
English (en)
Japanese (ja)
Other versions
JP4833059B2 (ja
JP2007516194A (ja
Filing date
Publication date
Priority claimed from GBGB0315657.7A external-priority patent/GB0315657D0/en
Priority claimed from GB0324919A external-priority patent/GB0324919D0/en
Application filed filed Critical
Priority claimed from PCT/GB2004/002824 external-priority patent/WO2005002552A2/en
Publication of JP2007516194A publication Critical patent/JP2007516194A/ja
Publication of JP2007516194A5 publication Critical patent/JP2007516194A5/ja
Application granted granted Critical
Publication of JP4833059B2 publication Critical patent/JP4833059B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2006518329A 2003-07-03 2004-07-05 医薬化合物 Expired - Fee Related JP4833059B2 (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US48468503P 2003-07-03 2003-07-03
GB0315657.7 2003-07-03
US60/484,685 2003-07-03
GBGB0315657.7A GB0315657D0 (en) 2003-07-03 2003-07-03 Pharmaceutical compounds
US51437403P 2003-10-24 2003-10-24
GB0324919.0 2003-10-24
GB0324919A GB0324919D0 (en) 2003-10-24 2003-10-24 Pharmaceutical compounds
US60/514,374 2003-10-24
PCT/GB2004/002824 WO2005002552A2 (en) 2003-07-03 2004-07-05 Benzimidazole derivatives and their use as protein kinases inhibitors

Publications (3)

Publication Number Publication Date
JP2007516194A JP2007516194A (ja) 2007-06-21
JP2007516194A5 true JP2007516194A5 (enExample) 2007-10-04
JP4833059B2 JP4833059B2 (ja) 2011-12-07

Family

ID=46045485

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006518329A Expired - Fee Related JP4833059B2 (ja) 2003-07-03 2004-07-05 医薬化合物

Country Status (15)

Country Link
US (3) US7977477B2 (enExample)
EP (2) EP1648426B1 (enExample)
JP (1) JP4833059B2 (enExample)
CN (1) CN1845734B (enExample)
AU (1) AU2004253338B2 (enExample)
CA (1) CA2531050C (enExample)
DK (2) DK1648426T3 (enExample)
ES (2) ES2457466T3 (enExample)
MX (1) MXPA05014223A (enExample)
NZ (1) NZ543959A (enExample)
PL (2) PL2305250T3 (enExample)
PT (2) PT2305250E (enExample)
SI (2) SI1648426T1 (enExample)
TW (1) TWI372050B (enExample)
WO (1) WO2005002552A2 (enExample)

Families Citing this family (133)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI372050B (en) * 2003-07-03 2012-09-11 Astex Therapeutics Ltd (morpholin-4-ylmethyl-1h-benzimidazol-2-yl)-1h-pyrazoles
NZ544756A (en) 2003-07-22 2009-09-25 Astex Therapeutics Ltd 3,4-Disubstituted 1H-pyrazole compounds and their use as cyclin dependent kinases (CDK) and glycogen synthase kinase-3 (GSK-3) modulators
US7572914B2 (en) 2003-12-19 2009-08-11 Takeda Pharmaceutical Company Limited Kinase inhibitors
JP4960708B2 (ja) * 2004-01-30 2012-06-27 バーテックス ファーマシューティカルズ インコーポレイテッド Ａｔｐ結合カセットトランスポーターのモジュレーター
US7977322B2 (en) 2004-08-20 2011-07-12 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
WO2006003440A1 (en) * 2004-07-05 2006-01-12 Astex Therapeutics Limited 3,4-disubstituted pyrazoles as cyclin dependent kinases (cdk) or aurora kinase or glycogen synthase 3 (gsk-3) inhibitors
WO2006023931A2 (en) 2004-08-18 2006-03-02 Takeda San Diego, Inc. Kinase inhibitors
US7713973B2 (en) 2004-10-15 2010-05-11 Takeda Pharmaceutical Company Limited Kinase inhibitors
CA2587489C (en) 2004-11-03 2013-12-31 Curis, Inc. Mediators of hedgehog signaling pathways, compositions and uses related thereto
EP1836199A1 (en) 2004-12-30 2007-09-26 Astex Therapeutics Limited Thiazole and isothiazole derivatives that modulate the activity of cdk, gsk and aurora kinases
EP2395000A1 (en) * 2004-12-30 2011-12-14 Astex Therapeutics Limited Benzimidazole compounds that modulate the activity of CDK, GSK and aurora kinases
JP2008526723A (ja) * 2004-12-30 2008-07-24 アステックス、セラピューティックス、リミテッド Ｃｄｋ、ｇｓｋ及びオーロラキナーゼの活性を調節するピラゾール誘導体
AR052559A1 (es) * 2005-01-21 2007-03-21 Astex Therapeutics Ltd Derivados de pirazol para inhibir cdk's y gsk's
US8404718B2 (en) 2005-01-21 2013-03-26 Astex Therapeutics Limited Combinations of pyrazole kinase inhibitors
RU2436575C2 (ru) * 2005-01-21 2011-12-20 Астекс Терапьютикс Лимитед Соединения для использования в фармацевтике
EP1845973B1 (en) 2005-01-21 2015-08-12 Astex Therapeutics Limited Pharmaceutical compounds
AU2006207321B2 (en) * 2005-01-21 2012-09-06 Astex Therapeutics Limited Pharmaceutical compounds
AR054425A1 (es) 2005-01-21 2007-06-27 Astex Therapeutics Ltd Sales de adicion de piperidin 4-il- amida de acido 4-(2,6-dicloro-benzoilamino) 1h-pirazol-3-carboxilico.
US20090156582A1 (en) * 2005-02-09 2009-06-18 Tetsuya Tsukamoto Pyrazole Compound
AU2006233537A1 (en) 2005-04-14 2006-10-19 F. Hoffmann-La Roche Ag Aminopyrazole derivatives, their manufacture and use as pharmaceutical agents
EP1749523A1 (en) * 2005-07-29 2007-02-07 Neuropharma, S.A. GSK-3 inhibitors
US8093401B2 (en) 2005-08-04 2012-01-10 Sirtris Pharmaceuticals, Inc. Sirtuin modulating compounds
US8088928B2 (en) 2005-08-04 2012-01-03 Sirtris Pharmaceuticals, Inc. Sirtuin modulating compounds
US7855289B2 (en) 2005-08-04 2010-12-21 Sirtris Pharmaceuticals, Inc. Sirtuin modulating compounds
CA2618370A1 (en) * 2005-08-04 2007-02-15 Sirtris Pharmaceuticals, Inc. Oxazolopyridine derivatives as sirtuin modulators
EP2258359A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis by muscarinic receptor modulation with sabcomelin
JP2009506069A (ja) 2005-08-26 2009-02-12 ブレインセルス，インコーポレイティド ムスカリン性受容体調節による神経発生
US8119655B2 (en) 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
JP2009512711A (ja) 2005-10-21 2009-03-26 ブレインセルス，インコーポレイティド Ｐｄｅ阻害による神経新生の調節
EP2314289A1 (en) 2005-10-31 2011-04-27 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
AU2006322187A1 (en) * 2005-12-08 2007-06-14 Novartis Ag Pyrazolo[1,5-a]pyridine-3-carboxylic acids as EphB and VEGFR2 kinase inhibitors
AU2006326247A1 (en) * 2005-12-15 2007-06-21 F. Hoffmann-La Roche Ag Tricyclic lactam derivatives, their manufacture and use as pharmaceutical agents
US7572809B2 (en) 2005-12-19 2009-08-11 Hoffmann-La Roche Inc. Isoquinoline aminopyrazole derivatives
WO2007077435A1 (en) * 2005-12-30 2007-07-12 Astex Therapeutics Limited Pharmaceutical compounds
KR20070077468A (ko) * 2006-01-23 2007-07-26 크리스탈지노믹스(주) 단백질 키나아제 활성을 저해하는 이미다조피리딘 유도체,이의 제조방법 및 이를 함유하는 약학 조성물
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
AU2007249399A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
WO2008001115A2 (en) * 2006-06-29 2008-01-03 Astex Therapeutics Limited Pharmaceutical combinations of 1-cyclopropyl-3- [3- (5-m0rphoolin-4-ylmethyl-1h-benzoimidazol-2-yl) -lh-1-pyrazol- 4-yl] -urea
EP2043635A2 (en) * 2006-06-29 2009-04-08 Astex Therapeutics Limited Pharmaceutical combinations
FR2903406B1 (fr) * 2006-07-04 2012-08-10 Aventis Pharma Sa Derives de pyrazolylbenzimidazole,compositions les contenant et utilisation
AU2007288245A1 (en) 2006-08-24 2008-02-28 Novartis Ag 2- (pyrazin-2-yl) -thiazole and 2- (1h-pyrazol-3-yl) -thiazole derivatives as well as related compounds as stearoyl-CoA desaturase (SCD) inhibitors for the treatment of metabolic, cardiovascular and other disorders
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
JP5351025B2 (ja) 2006-09-22 2013-11-27 ノバルティス アーゲー ヘテロ環式有機化合物
JPWO2008041767A1 (ja) * 2006-10-05 2010-02-04 萬有製薬株式会社 ＡｕｒｏｒａＡ阻害剤の薬効を予測又は診断する遺伝子・タンパク質マーカー
GEP20135728B (en) 2006-10-09 2013-01-25 Takeda Pharmaceuticals Co Kinase inhibitors
JP5528807B2 (ja) 2006-10-12 2014-06-25 アステックス、セラピューティックス、リミテッド 複合薬剤
JP5528806B2 (ja) 2006-10-12 2014-06-25 アステックス、セラピューティックス、リミテッド 複合薬剤
CA2673368C (en) 2006-12-19 2014-10-28 The Board Of Trustees Of The University Of Illinois 3-benzofuranyl-4-indolyl maleimides as potent gsk3 inhibitors for neurogenerative disorders
MX2009006728A (es) 2006-12-20 2009-09-09 Novartis Ag Heterociclos de 5 miembros 2-sustituidos como inhibidores de scd.
DE102006060598A1 (de) * 2006-12-21 2008-06-26 Merck Patent Gmbh Tetrahydrobenzoisoxazole
CL2008001822A1 (es) 2007-06-20 2009-03-13 Sirtris Pharmaceuticals Inc Compuestos derivados de tiazolo[5,4-b]piridina; composicion farmaceutica que comprende a dichos compuestos; y uso del compuesto en el tratamiento de la resistencia a la insulina, sindrome metabolico, diabetes, entre otras.
EP2217595A1 (en) * 2007-10-29 2010-08-18 Schering Corporation Diamido thiazole derivatives as protein kinase inhibitors
WO2009058728A1 (en) * 2007-10-29 2009-05-07 Schering Corporation Thiazole derivatives as protein kinase inhibitors
JP5544296B2 (ja) 2007-11-16 2014-07-09 ライジェル ファーマシューティカルズ， インコーポレイテッド 代謝障害のためのカルボキサミド、スルホンアミド、およびアミン化合物
ES2553340T3 (es) 2007-12-12 2015-12-07 Rigel Pharmaceuticals, Inc. Compuestos de carboxamida, sulfonamida y amina para trastornos metabólicos
NZ586756A (en) * 2008-01-22 2012-04-27 Vernalis R&D Ltd Indolyl-pyridone derivatives having checkpoint kinase 1 inhibitory activity
MX2010011288A (es) 2008-04-23 2010-11-09 Rigel Pharmaceuticals Inc Compuestos de carboxamida para el tratamiento de trastornos metabolicos.
CA2735593C (en) 2008-09-03 2017-08-15 Repligen Corporation Compositions including 6-aminohexanoic acid derivatives as hdac inhibitors
RU2539568C2 (ru) 2008-10-31 2015-01-20 Дженентек, Инк. Пиразолопиримидиновые соединения-ингибиторы jak и способы
MX2011005369A (es) * 2008-11-20 2011-06-20 Oncotherapy Science Inc Inhibidores de glicogeno sintasa cinasa-3 beta que contienen derivados de 7-hidroxi-benzoimidazol-4-il-metanona.
US8318928B2 (en) * 2008-12-15 2012-11-27 Glenmark Pharmaceuticals, S.A. Fused imidazole carboxamides as TRPV3 modulators
JP5628828B2 (ja) 2008-12-19 2014-11-19 サートリス ファーマシューティカルズ， インコーポレイテッド チアゾロピリジンサーチュイン調節化合物
MX2011006725A (es) 2008-12-22 2011-09-15 Millennium Pharm Inc Combinacion de inhibidores de aurora cinasa y anticuerpos anti-cd20.
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
UA103918C2 (en) 2009-03-02 2013-12-10 Айерем Элелси N-(hetero)aryl, 2-(hetero)aryl-substituted acetamides for use as wnt signaling modulators
EP2445885A4 (en) * 2009-06-25 2012-11-28 Medolution Ltd SUBSTITUTED HETEROCYCLIC COMPOUNDS AS CHINESE INHIBITORS AND METHOD FOR THEIR USE
UA110324C2 (en) * 2009-07-02 2015-12-25 Genentech Inc Jak inhibitory compounds based on pyrazolo pyrimidine
JP2013510824A (ja) * 2009-11-12 2013-03-28 セルビタ エス．エー． セリン／トレオニンキナーゼを調節または制御するための化合物、その調製のための方法、医薬組成物、化合物の使用、方法ならびにセリン／トレオニンキナーゼ調節剤
JP5488807B2 (ja) 2010-01-25 2014-05-14 日立工機株式会社 遠心分離機及び遠心分離機用スイングロータ
CN101857589B (zh) * 2010-06-08 2013-12-18 东南大学 吡唑-苯并咪唑类衍生物及其应用
KR101995013B1 (ko) 2010-07-13 2019-07-02 에프. 호프만-라 로슈 아게 Irak4 조절제로서 피라졸로[1,5a]피리미딘 및 티에노[3,2b]피리미딘 유도체
US10059723B2 (en) 2011-02-28 2018-08-28 Biomarin Pharmaceutical Inc. Histone deacetylase inhibitors
EP3524324A1 (en) 2011-02-28 2019-08-14 BioMarin Pharmaceutical Inc. Histone deacetylase inhibitors
US8957066B2 (en) 2011-02-28 2015-02-17 Biomarin Pharmaceutical Inc. Histone deacetylase inhibitors
GB201106817D0 (en) 2011-04-21 2011-06-01 Astex Therapeutics Ltd New compound
US9303024B2 (en) 2011-10-11 2016-04-05 Dana-Farber Cancer Institute, Inc. Pyrazol-3-ones that activate pro-apoptotic BAX
PH12017500997A1 (en) 2012-04-04 2018-02-19 Samumed Llc Indazole inhibitors of the wnt signal pathway and therapeutic uses thereof
GB201211021D0 (en) * 2012-06-21 2012-08-01 Cancer Rec Tech Ltd Pharmaceutically active compounds
TW201406758A (zh) * 2012-06-28 2014-02-16 Daiichi Sankyo Co Ltd 三環性化合物
US9980973B2 (en) 2012-10-19 2018-05-29 Astex Therapeutics Limited Bicyclic heterocycle compounds and their uses in therapy
GB201218864D0 (en) 2012-10-19 2012-12-05 Astex Therapeutics Ltd Bicyclic heterocycle compounds and their uses in therapy
GB201218862D0 (en) 2012-10-19 2012-12-05 Astex Therapeutics Ltd Bicyclic heterocycle compounds and their uses in therapy
GB201218850D0 (en) 2012-10-19 2012-12-05 Astex Therapeutics Ltd Bicyclic heterocycle compounds and their uses in therapy
CN104640850A (zh) * 2012-10-26 2015-05-20 霍夫曼-拉罗奇有限公司 3,4-二取代的1h-吡唑和4,5-二取代的噻唑的syk抑制剂
US10029988B2 (en) 2013-03-15 2018-07-24 Biomarin Pharmaceutical Inc. HDAC inhibitors
JO3368B1 (ar) 2013-06-04 2019-03-13 Janssen Pharmaceutica Nv مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
CN104211692B (zh) * 2013-06-04 2019-05-24 广东东阳光药业有限公司 作为欧若拉激酶抑制剂的衍生物
CN104447701B (zh) * 2013-09-17 2019-03-22 广东东阳光药业有限公司 吡唑类衍生物及其用途
US10335494B2 (en) 2013-12-06 2019-07-02 Millennium Pharmaceuticals, Inc. Combination of aurora kinase inhibitors and anti-CD30 antibodies
SG10201808102WA (en) 2013-12-20 2018-10-30 Astex Therapeutics Ltd Bicyclic heterocycle compounds and their uses in therapy
PE20211782A1 (es) 2014-05-23 2021-09-08 Hoffmann La Roche Compuestos de 5-cloro-2-difluorometoxifenil pirazolopirimidina, composiciones y metodos de uso de los mismos
JOP20150179B1 (ar) 2014-08-01 2021-08-17 Janssen Pharmaceutica Nv مركبات 6 ، 7 ثاني هيدرو بيرازولو [ 1، 5 الفا ] بيرازين – 4 (5 يد) – اون واستخدامها كمنظمات الوسترية سلبية لمستقبلات ملجور 2
JOP20150177B1 (ar) 2014-08-01 2021-08-17 Janssen Pharmaceutica Nv مركبات 6 ، 7 ثاني هيدرو بيرازولو [ 1، 5 الفا ] بيرازين – 4 (5 يد) – اون واستخدامها كمنظمات الوسترية سلبية لمستقبلات ملجور 2
EP3179991B1 (en) 2014-08-11 2021-10-06 Acerta Pharma B.V. Therapeutic combinations of a btk inhibitor and a bcl-2 inhibitor
SI3179992T1 (sl) 2014-08-11 2022-09-30 Acerta Pharma B.V. Terapevtske kombinacije zaviralca BTK, zaviralca PD-1 in/ali zaviralca PD-L1
AR101504A1 (es) 2014-08-11 2016-12-21 Acerta Pharma Bv Combinaciones terapéuticas de un inhibidor de la btk, un inhibidor de la pi3k, un inhibidor de la jak-2, y/o un inhibidor de la cdk4/6
JP6861154B2 (ja) 2014-12-03 2021-04-21 ヤンセン ファーマシューティカ エヌ．ベー． 放射標識されたｍＧｌｕＲ２ ＰＥＴリガンド
JP6689856B2 (ja) 2014-12-03 2020-04-28 ヤンセン ファーマシューティカ エヌ．ベー． ６，７−ジヒドロピラゾロ［１，５−ａ］ピラジン−４（５Ｈ）−オン化合物およびＭＧＬＵＲ２受容体の負のアロステリック調節因子としてのそれらの使用
CN105801563B (zh) * 2015-01-15 2020-01-14 广东东阳光药业有限公司 吡唑类衍生物及其用途
SG11201707752SA (en) 2015-04-22 2017-11-29 Rigel Pharmaceuticals Inc Pyrazole compounds and method for making and using the compounds
WO2016202758A1 (en) * 2015-06-18 2016-12-22 Bayer Pharma Aktiengesellschaft Substituted 2-(1h-pyrazol-1-yl)-1h-benzimidazole compounds
JP2018524292A (ja) 2015-07-21 2018-08-30 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． オーロラキナーゼインヒビターと化学療法剤の投与
NZ742200A (en) 2015-11-06 2023-01-27 Samumed Llc Treatment of osteoarthritis
CA3003998A1 (en) 2015-12-18 2017-06-22 Janssen Pharmaceutica Nv Radiolabelled mglur2/3 pet ligands
US11045562B2 (en) 2015-12-18 2021-06-29 Janssen Pharmaceutica Nv Radiolabelled mGluR2/3 PET ligands
WO2017132511A1 (en) * 2016-01-27 2017-08-03 Southern Research Institute Benzimidazole compounds, use as inhibitors of wnt signaling pathway in cancers, and methods for preparation thereof
SI3464285T1 (sl) 2016-06-01 2023-02-28 Biosplice Therapeutics, Inc. Postopek za pripravo N-(5-(3-(7-(3-fluorofenil)-3H-imidazo(4,5-C)piridin-2-il)-1H-indazol-5- il)piridin-3-il)-3-metilbutanamida
JP2020510061A (ja) * 2017-03-14 2020-04-02 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ピラゾロクロロフェニル化合物、組成物及びその使用方法
RU2769696C2 (ru) 2017-05-22 2022-04-05 Ф. Хоффманн-Ля Рош Аг Терапевтические соединения и композиции и способы их применения
US11874276B2 (en) 2018-04-05 2024-01-16 Dana-Farber Cancer Institute, Inc. STING levels as a biomarker for cancer immunotherapy
EP3818044A1 (en) * 2018-07-03 2021-05-12 IFM Due, Inc. Compounds and compositions for treating conditions associated with sting activity
EP3906029A4 (en) 2018-12-31 2022-09-21 Biomea Fusion, LLC INHIBITORS OF MENIN-MLL INTERACTION
EA202191852A1 (ru) 2018-12-31 2022-03-18 Биомеа Фьюжн, Ллс Необратимые ингибиторы взаимодействия менин-mll
WO2020150552A2 (en) * 2019-01-17 2020-07-23 Samumed, Llc Methods of treating cartilage disorders through inhibition of clk and dyrk
CN113766915A (zh) * 2019-03-25 2021-12-07 纽约市哥伦比亚大学理事会 用于治疗糖尿病和与胰腺功能受损相关的其他疾患的选择性foxo抑制剂
WO2020224568A1 (en) 2019-05-05 2020-11-12 Qilu Regor Therapeutics Inc. Cdk inhibitors
CN112047932B (zh) * 2019-06-05 2022-11-08 中国药科大学 吡唑类脾酪氨酸激酶抑制剂及其制备方法与用途
US20220305048A1 (en) 2019-08-26 2022-09-29 Dana-Farber Cancer Institute, Inc. Use of heparin to promote type 1 interferon signaling
AU2020335903A1 (en) 2019-08-30 2022-03-24 Rigel Pharmaceuticals, Inc. Pyrazole compounds, formulations thereof, and a method for using the compounds and/or formulations
CN111004221B (zh) * 2019-12-13 2021-02-02 长治学院 一种嘧啶/苯并咪唑杂合物、制备方法及医药用途
CN112592839B (zh) * 2021-01-08 2022-08-19 浙江工业大学 一株降解氨基甲酸乙酯的米根霉及其应用
CN113149978A (zh) * 2021-02-04 2021-07-23 中国药科大学 一种中间体化合物、制备方法及其用途
US12357623B2 (en) 2021-03-03 2025-07-15 Rigel Pharmaceuticals, Inc. Method for treating a disease or condition using a pyrazole compound or formulation thereof
CN113549038B (zh) * 2021-07-07 2023-05-23 常州大学 多取代异苯并呋喃化合物及其用途
AU2022325861A1 (en) 2021-08-11 2024-02-29 Biomea Fusion, Inc. Covalent inhibitors of menin-mll interaction for diabetes mellitus
IL310717A (en) 2021-08-20 2024-04-01 Biomea Fusion Inc Crystalline form of N-[4-[4-(4-morpholinyl)-7H-PYRROLO[2,3-D]PYRIMIDIN-6-YL]PHENYL]-4-[[3(R)-[(1-OXO ] -2-PROPEN-1-YL)AMINO]-1-PIPERIDINYL]METHYL]-2-PYRIDINECARBOXAMIDE, IRREVERSIBLE MENIN-MLL INHIBITOR FOR CANCER TREATMENT
TW202346291A (zh) 2022-03-23 2023-12-01 美商雷傑製藥公司 作為ｉｒａｋ抑制劑的嘧啶—２—基—吡唑化合物
CN116178358B (zh) * 2022-11-04 2024-04-19 济南大学 一种靶向c-Src激酶SH3结构域的化合物及其应用
PY2389146A (es) * 2022-11-09 2025-06-23 Syngenta Crop Prot Ag Derivados de pirazol microbiocidas
TW202430528A (zh) 2023-01-18 2024-08-01 美商拜歐米富士恩股份有限公司 Ｎ－［４－［４－（４－嗎啉基）－７ｈ－吡咯並［２，３－ｄ］嘧啶－６－基］苯基］－４－［［３（ｒ）－［（１－氧代－２－丙烯－１－基）氨基］－１－哌啶基］甲基］－２－吡啶甲醯胺的結晶形式作為ｍｅｎｉｎ－ｍｌｌ相互作用的共價抑制劑
CN116675714B (zh) * 2023-05-04 2025-08-29 西南医科大学 一种靶向光敏剂FA-BAT-NPs及其制备方法与应用
WO2025040140A1 (en) * 2023-08-22 2025-02-27 National Institute Of Biological Sciences, Beijing Substituted pyrazol-4-yl urea as kinase inhibitors
WO2026024674A1 (en) 2024-07-22 2026-01-29 Genesis Therapeutics, Inc. Methods of treating skp2-associated cancers

Family Cites Families (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4431807A (en) 1980-06-12 1984-02-14 The United States Of America As Represented By The Secretary Of The Army 4-Methyl-5-(unsubstituted and substituted phenoxy)-6-methoxy-8-(aminoalkylamino)quinolines
US4619686A (en) 1984-07-17 1986-10-28 Eli Lilly And Company Pyridazinylurea compounds and methods of use as herbicides
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
EP0308020A3 (en) 1987-09-18 1990-12-05 Merck & Co. Inc. 5-(aryl and heteroaryl)-6-(aryl and heteroaryl)-1,2-dihydro-2-oxo 3-pyridinecarboxylic acids and derivatives thereof
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US5451596A (en) 1992-12-29 1995-09-19 Rhone Poulenc Rorer Pharmaceuticals Inc. Cycloalkyl amine bis-aryl squalene synthase inhibitors
FR2707295A1 (fr) 1993-06-07 1995-01-13 Rhone Poulenc Agrochimie Fongicides pyrazoles substitués en position 3 par un hétérocycle.
ES2172585T3 (es) 1994-05-31 2002-10-01 Mitsui Chemicals Inc Derivado de benzoimidazol.
DE69526790T2 (de) 1994-06-24 2003-03-06 Euroceltique S.A., Luxemburg/Luxembourg Verbindungen zur hemmung von phosphodiesrerase iv
ATE251141T1 (de) * 1995-03-10 2003-10-15 Berlex Lab Benzamidin-derivate, deren herstellung und deren verwendung als anti-koagulantien
US6218529B1 (en) 1995-07-31 2001-04-17 Urocor, Inc. Biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer
AU6966696A (en) 1995-10-05 1997-04-28 Warner-Lambert Company Method for treating and preventing inflammation and atherosclerosis
US5874452A (en) 1996-04-03 1999-02-23 Merck & Co., Inc. Biheteroaryl inhibitors of farnesyl-protein transferase
WO1997036585A1 (en) 1996-04-03 1997-10-09 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
CN1225629A (zh) * 1996-05-30 1999-08-11 霍夫曼-拉罗奇有限公司 新的吡咯衍生物
CA2744096C (en) 1996-07-31 2013-07-30 Laboratory Corporation Of America Holdings Biomarkers and targets for diagnosis, prognosis and management of prostate disease
US6569878B1 (en) 1997-10-27 2003-05-27 Agouron Pharmaceuticals Inc. Substituted 4-amino-thiazol-2-yl compounds as cyclin-dependent kinase inhibitors
WO1999046244A1 (en) 1998-03-12 1999-09-16 Novo Nordisk A/S Modulators of protein tyrosine phosphatases (ptpases)
ES2258331T3 (es) 1998-05-22 2006-08-16 Scios Inc. Compuestos heterociclicos y procedimientos de tratamiento de insuficiencia cardiaca y otros trastornos.
AU3127900A (en) 1998-12-23 2000-07-31 Du Pont Pharmaceuticals Company Thrombin or factor xa inhibitors
UA73492C2 (en) 1999-01-19 2005-08-15 Aromatic heterocyclic compounds as antiinflammatory agents
AU4327600A (en) 1999-04-02 2000-10-23 Du Pont Pharmaceuticals Company Aryl sulfonyls as factor xa inhibitors
PT1169038E (pt) 1999-04-15 2012-10-26 Bristol Myers Squibb Co Inibidores cíclicos da proteína tirosina cinase
EP1177187B1 (en) 1999-04-28 2007-07-25 Sanofi-Aventis Deutschland GmbH Di-aryl acid derivatives as ppar receptor ligands
DE19920936A1 (de) * 1999-05-07 2000-11-09 Basf Ag Heterozyklisch substituierte Benzimidazole, deren Herstellung und Anwendung
PT1194425E (pt) * 1999-06-23 2005-10-31 Aventis Pharma Gmbh Benzimidazoles substituidos
FR2795726A1 (fr) 1999-06-30 2001-01-05 Aventis Cropscience Sa Nouveaux pyrazoles fongicides
JP4627356B2 (ja) 1999-06-30 2011-02-09 昭 松森 ウイルス性心筋炎の予防または治療薬剤
PE20010306A1 (es) 1999-07-02 2001-03-29 Agouron Pharma Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa
US6632815B2 (en) 1999-09-17 2003-10-14 Millennium Pharmaceuticals, Inc. Inhibitors of factor Xa
ES2316383T3 (es) 1999-09-17 2009-04-16 Millennium Pharmaceuticals, Inc. Benzamidas e inhibidores relacionados del factor xa.
NZ517828A (en) 1999-09-17 2003-10-31 Millennium Pharm Inc Inhibitors having activity against mammalian factor Xa
YU54202A (sh) 2000-01-18 2006-01-16 Agouron Pharmaceuticals Inc. Jedinjenja indazola, farmaceutske smeše i postupci za stimulisanje i inhibiranje ćelijske proliferacije
HN2001000008A (es) 2000-01-21 2003-12-11 Inc Agouron Pharmaceuticals Compuesto de amida y composiciones farmaceuticas para inhibir proteinquinasas, y su modo de empleo
EP1200422A2 (en) 2000-02-05 2002-05-02 Vertex Pharmaceuticals Incorporated Pyrazole compositions useful as inhibitors of erk
AU2001250783A1 (en) * 2000-02-29 2001-09-12 Cor Therapeutics, Inc. Benzamides and related inhibitors of factor xa
WO2001068585A1 (en) 2000-03-14 2001-09-20 Fujisawa Pharmaceutical Co., Ltd. Novel amide compounds
HUP0300382A3 (en) 2000-03-29 2006-11-28 Cyclacel Ltd 2-substituted 4-heteroaryl-pyrimidines and their use in the treatmetn of proliferative disorders and pharmaceutical compositions containing the compounds
JP2004501083A (ja) 2000-04-18 2004-01-15 アゴーロン・ファーマシューティカルズ・インコーポレイテッド プロテインキナーゼを阻害するためのピラゾール
ES2236217T3 (es) 2000-04-25 2005-07-16 Bristol-Myers Squibb Company Uso de 5.tio.,sulfinil- y sulfonilpirazolo 3,4-b)-piridinas como inhibidores de la quinasa dependiente de la ciclina.
US6414013B1 (en) 2000-06-19 2002-07-02 Pharmacia & Upjohn S.P.A. Thiophene compounds, process for preparing the same, and pharmaceutical compositions containing the same background of the invention
BR0112292A (pt) 2000-06-23 2003-06-24 Bristol Myers Squibb Pharma Co Composto, composição farmacêutica, método para tratar ou prevenir disfunções tromboembólicas e uso de um composto
AU2001268711A1 (en) 2000-06-23 2002-01-08 Bristol-Myers Squibb Pharma Company Heteroaryl-phenyl substituted factor xa inhibitors
AU2001273040A1 (en) 2000-06-27 2002-01-08 Du Pont Pharmaceuticals Company Factor xa inhibitors
JP2004524277A (ja) 2000-10-20 2004-08-12 ブリストル−マイヤーズ スクイブ ファーマ カンパニー アシルセミカルバジド及びサイクリン依存性キナーゼ（ｃｄｋ）阻害剤としてのその使用
HUP0400639A3 (en) * 2000-12-21 2010-03-29 Vertex Pharma Pyrazole compounds useful as protein kinase inhibitors and pharmaceutical compositions containing them
DE10108480A1 (de) * 2001-02-22 2002-09-05 Bayer Ag Pyrazolylpyrimidine
DE10110750A1 (de) * 2001-03-07 2002-09-12 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
EP1377549A1 (en) 2001-03-12 2004-01-07 Millennium Pharmaceuticals, Inc. Functionalized heterocycles as modulators of chemokine receptor function and methods of use therefor
EP1397137B1 (en) 2001-05-25 2009-10-14 Bristol-Myers Squibb Company Hydantion derivatives as inhibitors of matrix metalloproteinases
DK1401837T3 (da) 2001-06-29 2005-11-07 Cv Therapeutics Inc Purinderivater som A2B-adenosinreceptorantagonister
JP2004536113A (ja) 2001-07-03 2004-12-02 カイロン コーポレイション チロシンキナーゼおよびセリン／スレオニンキナーゼのインヒビターとしてのインダゾールベンズイミダゾール化合物
WO2003006465A1 (en) 2001-07-13 2003-01-23 Cv Therapeutics, Inc. Partial and full agonist of a adenosine receptors
US6897208B2 (en) * 2001-10-26 2005-05-24 Aventis Pharmaceuticals Inc. Benzimidazoles
FR2831536A1 (fr) * 2001-10-26 2003-05-02 Aventis Pharma Sa Nouveaux derives de benzimidazoles, leur procede de preparation, leur application a titre de medicament, compositions pharmaceutiques et nouvelle utilisation notamment comme inhibiteurs de kdr
MXPA04003954A (es) * 2001-10-26 2004-11-29 Aventis Pharma Inc Bencimidazoles.
EP1314733A1 (en) 2001-11-22 2003-05-28 Aventis Pharma Deutschland GmbH Indole-2-carboxamides as factor Xa inhibitors
EP1460067A4 (en) 2001-11-26 2005-12-07 Takeda Pharmaceutical BICYCLIC DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE
AU2002357312A1 (en) 2001-12-20 2003-07-09 Bristol-Myers Squibb Company Barbituric acid derivatives as inhibitors of tnf-alpha converting enzyme (tace) and/or matrix metalloproteinases
KR20040084896A (ko) 2002-02-06 2004-10-06 버텍스 파마슈티칼스 인코포레이티드 Ｇｓｋ-3의 억제제로서 유용한 헤테로아릴 화합물
AU2003286757B2 (en) 2002-11-01 2009-06-04 Merck Sharp & Dohme Corp. Carbonylamino-benzimidazole derivatives as androgen receptor modulators
WO2004050636A2 (en) 2002-12-04 2004-06-17 Aventis Pharma Deutschland Gmbh IMIDAZOLE-DERIVATIVES AS FACTOR Xa INHIBITORS
EP1572212A2 (en) 2002-12-11 2005-09-14 7TM Pharma A/S Quinoline compounds for use in mch receptor related disorders
EP1581527A4 (en) 2002-12-13 2006-11-22 Smithkline Beecham Corp MIMETICS OF THROMBOPOIETINE
BR0317659A (pt) 2002-12-23 2005-12-06 Aventis Pharma Gmbh Derivados de pirazol como inibidores de fator xa
US20040242559A1 (en) * 2003-04-25 2004-12-02 Aventis Pharma S.A. Novel indole derivatives, preparation thereof as medicinal products and pharmaceutical compositions, and especially as KDR inhibitors
FR2854159B1 (fr) * 2003-04-25 2008-01-11 Aventis Pharma Sa Nouveaux derives de l'indole, leur preparation a titre de medicaments, compositions pharmaceutiques et notamment comme inhibiteurs de kdr
TWI372050B (en) * 2003-07-03 2012-09-11 Astex Therapeutics Ltd (morpholin-4-ylmethyl-1h-benzimidazol-2-yl)-1h-pyrazoles
GB0315657D0 (en) * 2003-07-03 2003-08-13 Astex Technology Ltd Pharmaceutical compounds
US20050032869A1 (en) 2003-07-08 2005-02-10 Pharmacia Italia S.P.A. Pyrazolyl-indole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
WO2005028624A2 (en) 2003-09-15 2005-03-31 Plexxikon, Inc. Molecular scaffolds for kinase ligand development
US8969372B2 (en) 2003-11-14 2015-03-03 Aptose Boisciences Inc. Aryl imidazoles and their use as anti-cancer agents
CA2558600C (en) * 2004-03-10 2013-07-09 Kureha Corporation A substituted-trialkyl amine compound with anti-viral activity based on antagonism against a chemokine receptor cxcr4
EP1836199A1 (en) * 2004-12-30 2007-09-26 Astex Therapeutics Limited Thiazole and isothiazole derivatives that modulate the activity of cdk, gsk and aurora kinases
EP2395000A1 (en) * 2004-12-30 2011-12-14 Astex Therapeutics Limited Benzimidazole compounds that modulate the activity of CDK, GSK and aurora kinases
WO2007077435A1 (en) 2005-12-30 2007-07-12 Astex Therapeutics Limited Pharmaceutical compounds
WO2008001115A2 (en) 2006-06-29 2008-01-03 Astex Therapeutics Limited Pharmaceutical combinations of 1-cyclopropyl-3- [3- (5-m0rphoolin-4-ylmethyl-1h-benzoimidazol-2-yl) -lh-1-pyrazol- 4-yl] -urea
EP2043635A2 (en) * 2006-06-29 2009-04-08 Astex Therapeutics Limited Pharmaceutical combinations
JP5528807B2 (ja) * 2006-10-12 2014-06-25 アステックス、セラピューティックス、リミテッド 複合薬剤

Similar Documents

Publication Publication Date Title
JP2007516194A5 (enExample)
JP7337883B2 (ja) 乳酸脱水素酵素の小分子阻害剤及びその使用方法
JP6889689B2 (ja) プロテインキナーゼコンジュゲート及びインヒビター
AU2015353210B2 (en) 2-aminopyrimidine compound and pharmaceutical composition and use thereof
Desai et al. Oxadiazole: A highly versatile scaffold in drug discovery
JP5756518B2 (ja) 複素環アルキニルベンゼン化合物と、その医療用組成物および使用
EP2968360B1 (en) Quinolinone derivatives for the inhibition of bromodomain-containing proteins
Bode et al. Imidazo [1, 2-a] pyridin-3-amines as potential HIV-1 non-nucleoside reverse transcriptase inhibitors
Kmentova et al. Synthesis and structure− activity relationships of aza-and diazabiphenyl analogues of the antitubercular drug (6 S)-2-Nitro-6-{[4-(trifluoromethoxy) benzyl] oxy}-6, 7-dihydro-5 H-imidazo [2, 1-b][1, 3] oxazine (PA-824)
EP2207773B1 (en) Heterocyclic compound and pharmaceutical composition thereof
CN114072387B (zh) 吲唑类化合物及其药用组合物和应用
KR20250025634A (ko) 피리딘 관문 키나제 1(chk1) 억제제 및 그의 용도
AU2019246753A1 (en) Novel compounds and compositions for inhibition of FASN
DK2953943T3 (en) Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity
BR112013029508A2 (pt) composto, composição farmacêutica, e, uso do referido composto
BR112019011035A2 (pt) métodos de uso de compostos pirazol e pirazol substituído e para o tratamento de doenças hiperproliferativas
RU2018134981A (ru) Конъюгаты, содержащие ингибиторы RIPK2
JP2008526721A5 (enExample)
CN101370789A (zh) 作为组蛋白脱乙酰酶抑制剂的吡啶和嘧啶衍生物
CN107428690A (zh) 可用于治疗癌症的突变idh1抑制剂
Ghomashi et al. Recent advances in biological active sulfonamide based hybrid compounds part A: Two-component sulfonamide hybrids
JP2012529513A (ja) トリアジン誘導体類及びそれらの治療応用
Im et al. Discovery of 4-arylamido 3-methyl isoxazole derivatives as novel FMS kinase inhibitors
EP3004088A1 (en) Slc2a transporter inhibitors
Yang et al. Design, synthesis and biological evaluation of 2-((4-sulfamoylphenyl) amino)-pyrrolo [2, 3-d] pyrimidine derivatives as CDK inhibitors